356 related articles for article (PubMed ID: 33925949)
1. Tinkering under the Hood: Metabolic Optimisation of CAR-T Cell Therapy.
Jenkins Y; Zabkiewicz J; Ottmann O; Jones N
Antibodies (Basel); 2021 Apr; 10(2):. PubMed ID: 33925949
[TBL] [Abstract][Full Text] [Related]
2. Metabolic and Mitochondrial Functioning in Chimeric Antigen Receptor (CAR)-T Cells.
Rad S M AH; Halpin JC; Mollaei M; Smith Bell SWJ; Hirankarn N; McLellan AD
Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33799768
[TBL] [Abstract][Full Text] [Related]
3. Importance of T, NK, CAR T and CAR NK Cell Metabolic Fitness for Effective Anti-Cancer Therapy: A Continuous Learning Process Allowing the Optimization of T, NK and CAR-Based Anti-Cancer Therapies.
Krug A; Martinez-Turtos A; Verhoeyen E
Cancers (Basel); 2021 Dec; 14(1):. PubMed ID: 35008348
[TBL] [Abstract][Full Text] [Related]
4. Tumor Microenvironment Immunosuppression: A Roadblock to CAR T-Cell Advancement in Solid Tumors.
Johnson A; Townsend M; O'Neill K
Cells; 2022 Nov; 11(22):. PubMed ID: 36429054
[TBL] [Abstract][Full Text] [Related]
5. Role of CAR T Cell Metabolism for Therapeutic Efficacy.
Rial Saborido J; Völkl S; Aigner M; Mackensen A; Mougiakakos D
Cancers (Basel); 2022 Nov; 14(21):. PubMed ID: 36358860
[TBL] [Abstract][Full Text] [Related]
6. Befriending the Hostile Tumor Microenvironment in CAR T-Cell Therapy.
Lindo L; Wilkinson LH; Hay KA
Front Immunol; 2020; 11():618387. PubMed ID: 33643299
[TBL] [Abstract][Full Text] [Related]
7. Engineering Metabolism of Chimeric Antigen Receptor (CAR) Cells for Developing Efficient Immunotherapies.
Mangal JL; Handlos JL; Esrafili A; Inamdar S; Mcmillian S; Wankhede M; Gottardi R; Acharya AP
Cancers (Basel); 2021 Mar; 13(5):. PubMed ID: 33807867
[TBL] [Abstract][Full Text] [Related]
8. Cutting-Edge CAR Engineering: Beyond T Cells.
Chocarro L; Blanco E; Fernández-Rubio L; Arasanz H; Bocanegra A; Echaide M; Garnica M; Ramos P; Piñeiro-Hermida S; Vera R; Kochan G; Escors D
Biomedicines; 2022 Nov; 10(12):. PubMed ID: 36551788
[TBL] [Abstract][Full Text] [Related]
9. Challenges and Prospects of Chimeric Antigen Receptor T-cell Therapy for Metastatic Prostate Cancer.
Gorchakov AA; Kulemzin SV; Kochneva GV; Taranin AV
Eur Urol; 2020 Mar; 77(3):299-308. PubMed ID: 31471138
[TBL] [Abstract][Full Text] [Related]
10. Target selection of CAR T cell therapy in accordance with the TME for solid tumors.
Liu B; Yan L; Zhou M
Am J Cancer Res; 2019; 9(2):228-241. PubMed ID: 30906625
[TBL] [Abstract][Full Text] [Related]
11. Engineering Next-Generation CAR-T Cells: Overcoming Tumor Hypoxia and Metabolism.
Gao TA; Chen YY
Annu Rev Chem Biomol Eng; 2022 Jun; 13():193-216. PubMed ID: 35700528
[TBL] [Abstract][Full Text] [Related]
12. Engineering chimeric antigen receptor T cells for solid tumour therapy.
Liu L; Qu Y; Cheng L; Yoon CW; He P; Monther A; Guo T; Chittle S; Wang Y
Clin Transl Med; 2022 Dec; 12(12):e1141. PubMed ID: 36495108
[TBL] [Abstract][Full Text] [Related]
13. Remodeling metabolic fitness: Strategies for improving the efficacy of chimeric antigen receptor T cell therapy.
Shen L; Xiao Y; Tian J; Lu Z
Cancer Lett; 2022 Mar; 529():139-152. PubMed ID: 35007698
[TBL] [Abstract][Full Text] [Related]
14. A Metabolism Toolbox for CAR T Therapy.
Xu X; Gnanaprakasam JNR; Sherman J; Wang R
Front Oncol; 2019; 9():322. PubMed ID: 31114756
[TBL] [Abstract][Full Text] [Related]
15. Chimeric Antigen Receptors for the Tumour Microenvironment.
Habib R; Nagrial A; Micklethwaite K; Gowrishankar K
Adv Exp Med Biol; 2020; 1263():117-143. PubMed ID: 32588326
[TBL] [Abstract][Full Text] [Related]
16. Metabolic and epigenetic orchestration of (CAR) T cell fate and function.
Akbari B; Hosseini Z; Shahabinejad P; Ghassemi S; Mirzaei HR; O'Connor RS
Cancer Lett; 2022 Dec; 550():215948. PubMed ID: 36209973
[TBL] [Abstract][Full Text] [Related]
17. Pre-conditioning modifies the TME to enhance solid tumor CAR T cell efficacy and endogenous protective immunity.
Murad JP; Tilakawardane D; Park AK; Lopez LS; Young CA; Gibson J; Yamaguchi Y; Lee HJ; Kennewick KT; Gittins BJ; Chang WC; Tran CP; Martinez C; Wu AM; Reiter RE; Dorff TB; Forman SJ; Priceman SJ
Mol Ther; 2021 Jul; 29(7):2335-2349. PubMed ID: 33647456
[TBL] [Abstract][Full Text] [Related]
18. CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment.
Martinez M; Moon EK
Front Immunol; 2019; 10():128. PubMed ID: 30804938
[TBL] [Abstract][Full Text] [Related]
19. Disruption of adenosine 2A receptor improves the anti-tumor function of anti-mesothelin CAR T cells both in vitro and in vivo.
Liu G; Zhang Q; Liu G; Li D; Zhang L; Gu Z; Tian H; Zhang Y; Tian X
Exp Cell Res; 2021 Dec; 409(1):112886. PubMed ID: 34673000
[TBL] [Abstract][Full Text] [Related]
20. Remodelling of tumour microenvironment by microwave ablation potentiates immunotherapy of AXL-specific CAR T cells against non-small cell lung cancer.
Cao B; Liu M; Wang L; Zhu K; Cai M; Chen X; Feng Y; Yang S; Fu S; Zhi C; Ye X; Zhang J; Zhang Z; Yang X; Zhao M; Wu Q; Xu L; Yang L; Lian H; Zhao Q; Zhang Z
Nat Commun; 2022 Oct; 13(1):6203. PubMed ID: 36261437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
